Heart failure and diabetes mellitus: Epidemiology and management of an alarming association

被引:80
作者
Cohen-Solal, Alain [1 ,2 ]
Beauvais, Florence [1 ]
Logeart, Damien [1 ]
机构
[1] Hop Lariboisiere, F-75010 Paris, France
[2] Fac Denis Diderot, INSERM, U689, Paris, France
关键词
angiotensin-converting enzyme inhibitors; beta-blockers; diabetes; diagnosis; epidemiology; glitazones; heart failure; metformin;
D O I
10.1016/j.cardfail.2008.04.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus is a growing epidemic with a prevalence among patients with heart failure (HF) approaching 30%. Diabetes worsens the prognosis of HF, and the pathophysiology is complex and multifactorial. Early detection of subtle alterations in cardiac function by modern tools, Such as Doppler echocardiography or brain natriuretic peptide dosage, is thus important in these patients. All drugs known to be effective in HF with systolic dysfunction are also effective in patients with diabetes. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists also seem particularly useful. Overall, however, little is known about the treatment of diabetic patients with HF, especially in case of preserved systolic function. Ongoing and future trials should help to determine the best treatment for these patients with or without associated diabetes. This review assesses the relationships between diabetes mellitus and HF and discusses the various medical strategies.
引用
收藏
页码:615 / 625
页数:11
相关论文
共 96 条
[1]   Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE) [J].
Adams, KF ;
Fonarow, GC ;
Emerman, CL ;
LeJemtel, TH ;
Costanzo, MR ;
Abraham, WT ;
Berkowitz, RL ;
Galvao, M ;
Horton, DP .
AMERICAN HEART JOURNAL, 2005, 149 (02) :209-216
[2]   Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study [J].
Arnold, JMO ;
Yusuf, S ;
Young, J ;
Mathew, J ;
Johnstone, D ;
Avezum, A ;
Lonn, E ;
Pogue, J ;
Bosch, J .
CIRCULATION, 2003, 107 (09) :1284-1290
[3]   Effects of glucose intolerance on myocardial function and collagen-linked glycation [J].
Avendano, GF ;
Agarwal, RK ;
Bashey, RI ;
Lyons, MM ;
Soni, BJ ;
Jyothirmayi, GN ;
Regan, TJ .
DIABETES, 1999, 48 (07) :1443-1447
[4]   ESTIMATING CLINICAL MORBIDITY DUE TO ISCHEMIC-HEART-DISEASE AND CONGESTIVE-HEART-FAILURE - THE FUTURE RISE OF HEART-FAILURE [J].
BONNEUX, L ;
BARENDREGT, JJ ;
MEETER, K ;
BONSEL, GJ ;
van der Maas, PJ .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1994, 84 (01) :20-28
[5]  
Bosch J, 2006, NEW ENGL J MED, V355, P1551
[6]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[7]   The final 10-year follow-up results from the BARI randomized trial [J].
Brooks, Maria Mori ;
Alderman, Edwin L. ;
Bates, Eric ;
Bourassa, Martial ;
Califf, Robert M. ;
Chaitman, Bernard R. ;
Detre, Katherine M. ;
Feit, Frederick ;
Frye, Robert L. ;
Gibbons, Raymond J. ;
Hardison, Regina M. ;
Hlatky, Mark A. ;
Holmes, David R., Jr. ;
Jacobs, Alice K. ;
Kelsey, Sheryl F. ;
Krauland, Mary ;
Rogers, William J. ;
Schaff, Hartzell V. ;
Schwartz, Leonard ;
Sutton-Tyrrell, Kim ;
Williams, David O. ;
Whitlow, Patrick K. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (15) :1600-1606
[8]   Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial [J].
Brooks, Maria Mori ;
Frye, Robert L. ;
Genuth, Saul ;
Detre, Katherine M. ;
Nesto, Richard ;
Sobel, Burton E. ;
Kelsey, Sheryl F. ;
Orchard, Trevor J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12A) :9G-19G
[9]   A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes [J].
Candido, R ;
Forbes, JM ;
Thomas, MC ;
Thallas, V ;
Dean, RG ;
Burns, WC ;
Tikellis, C ;
Ritchie, RH ;
Twigg, SM ;
Cooper, ME ;
Burrell, LM .
CIRCULATION RESEARCH, 2003, 92 (07) :785-792
[10]   The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: Rationale and design [J].
Carson, P ;
Massie, BM ;
McKelvie, R ;
McMurray, J ;
Komajda, M ;
Zile, M ;
Ptaszynska, A ;
Frangin, G .
JOURNAL OF CARDIAC FAILURE, 2005, 11 (08) :576-585